Additional Math Model Extensions for Thermoregulation
Certainty: 0.25. The spare respiratory capacity model (ch06:Spare Respiratory Capacity as Thermoregulatory Capacity Proxy in ME/CFS) can be formalized as an ODE where thermoregulatory work demand W_th (sum of sweating, shivering, and vasomotor ATP costs) depletes mitochondrial reserve R_s(t). When W_th exceeds R_s, fatigue accumulates at rate proportional to the deficit. The model predicts that ME/CFS patients (R_s reduced ~50%) accumulate fatigue 3x faster under thermal stress; pre-conditioning via WBH extends tolerance linearly with R_s improvement. No ME/CFS mitochondrial-reserve coupling data.
Certainty: 0.20. TRPM3-TRPV1 functional antagonism can be modeled as coupled channel activities where TRPM3 tonically inhibits TRPV1, and TRPM3 autoantibody concentration A_ab modulates the inhibition strength. In ME/CFS (A_ab elevated), TRPM3-mediated TRPV1 suppression is weakened, causing TRPV1 hyperresponsiveness to heat β producing global thermosensing failure plus paradoxical heat hyperexcitability. Falsifiable: TRPM3 calcium influx correlates inversely with TRPV1 CGRP release r below -0.5 in ME/CFS sensory neurons. No ME/CFS TRPM3-TRPV1 modeling data.
Certainty: 0.25. HSP70 binds and inhibits PERK kinase, attenuating the integrated stress response (ISR). An ODE coupling HSP70 concentration H70(t) to PERK activity P(t) via reversible binding predicts that ME/CFS (basal H70 reduced) operates with chronically elevated ISR. Thermal or pharmacological HSP70 induction above a threshold (H70 > 0.5 normalized) reduces ISR; excessive HSP70 (>2x baseline) may cause ISR overshoot. This defines a therapeutic window for HSP70-targeted interventions. No ME/CFS HSP70-PERK coupling data.
Certainty: 0.20. Cold intolerance via failed BAT activation (ch10:Could Cold Intolerance Reflect Failed Brown Adipose Tissue Activation via Sympathetic Dysfunction?) can be modeled as a threshold phenomenon: sympathetic drive S_d must exceed BAT activation threshold B_th for UCP1-dependent thermogenesis to initiate. ME/CFS (B_th elevated from sympathetic desensitization) shows absent BAT activation at moderate cold stress where healthy controls activate normally. Beta3-agonists (mirabegron) lower B_th, restoring BAT activation at lower sympathetic drive. No ME/CFS BAT threshold data.
Certainty: 0.25. Thermal therapy response R(T_dose, S) as a function of thermal dose T_dose and disease severity S can be modeled as a U-shaped curve where the optimal dose T_opt(S) = T_healthy x (1 - beta x S) decreases with severity. Mild patients benefit from higher doses (~80% of healthy optimum); severe patients require much lower doses (~50% of healthy optimum) due to narrower tolerance window. Falsifiable: severe ME/CFS patients show better response at lower thermal doses than mild patients in a dose-finding crossover trial. No ME/CFS thermal dose-response data.
Certainty: 0.20. The autophagy switch hypothesis (ch06:Heat-Induced Autophagy Switch: Selective-to-Bulk Transition via HSP70 Redistribution) can be formalized as HSP70 chaperone allocation between selective autophagy A_s and bulk autophagy A_b, where A_s is HSP70-dependent and A_b is HSP70-inhibited. ME/CFS simulation (HSP70 chronic low) shows A_s up, A_b suppression, mitochondrial health decline. WBH increases HSP70, reversing the allocation: A_s down, A_b up, mitochondrial health improves. The switch triggers at a critical HSP70 threshold. No ME/CFS autophagy-switch data.
Certainty: 0.20. The molecular (HSP70, ET-1), cellular (mitochondrial reserve, autophagy), organ (circadian oscillators, vasomotor), and clinical (fatigue, thermal tolerance) layers can be integrated into a multi-scale ODE framework. Cross-layer coupling reveals intervention cross-effects: ET-1 reduction improves both circadian (organ) and vasomotor (organ) function; HSP70 induction benefits mitochondria (cellular), autophagy (cellular), and fatigue (clinical). Falsifiable: the model predicts at least one non-obvious cross-effect (e.g., ET-1 antagonist improves mitochondrial function) that is verified in linked clinical measurements. No ME/CFS multi-scale model data.
Certainty: 0.20. ME/CFS thermoregulatory heterogeneity β some patients tolerate heat but not cold, others neither β can be captured by sampling individual resilience parameters (HSP70 sensitivity, ET-1 baseline, spare respiratory capacity, BAT threshold, vasomotor bias) from population distributions. Stochastic simulation predicts three responder clusters: heat-tolerant (30%), cold-tolerant (25%), and mixed-intolerant (45% non-responders requiring combination therapy). Falsifiable: cluster analysis of thermal challenge responses in n >= 50 ME/CFS patients identifies the predicted proportions. No ME/CFS stochastic modeling data.
Could a cholinergic precursor stack β alpha-GPC (600 mg), Huperzine A (50-100 Β΅g), CDP-choline (500 mg) β enhance vagal efferent tone and the cholinergic anti-inflammatory pathway in ME/CFS? The rationale: augmenting central and peripheral ACh availability should improve GI motility (M3 receptor), CAP-mediated TNF-Ξ± suppression, and cardiac vagal tone (HRV). However, Huperzine A at even low doses carries risk of cholinergic excess (bradycardia, salivation, diarrhea). No ME/CFS trials exist. Whether vagal tone enhancement in the presence of GPCR autoantibodies (M2/M4) can overcome receptor blockade is unknown. (Blitshteyn, Doherty, and Steinman 2026)
Falsifiable prediction: Open-label pilot (n=20, 8 weeks) will show HRV rMSSD increase β₯15%, fatigue reduction β₯8 points (MFI), and GI symptom reduction β₯20% (GSRS). Falsified if fewer than 3 of 5 participants show improvement in β₯2 domains.
Could a glial modulation stack β palmitoylethanolamide (PEA, 400 mg bid), luteolin (100 mg qd), pterostilbene (50 mg bid) β reduce microglial activation in the dorsolateral medulla and improve autonomic function? PEA activates PPAR-Ξ± on microglia reducing TNF-Ξ±/IL-1Ξ² release. Luteolin inhibits TLR4/MyD88 on microglia and mast cells. Pterostilbene activates SIRT1/NRF2 reducing oxidative stress. The combination targets the brainstem neuroinflammation mechanism proposed by Blitshteyn 2025. All three are available as supplements but have not been tested in ME/CFS as a combination, and no human TSPO-PET studies exist to confirm target engagement in brainstem microglia. (Blitshteyn 2025)
Falsifiable prediction: Open-label pilot (n=20, 12 weeks) will show TSPO-PET SUVR decrease β₯15% in dorsolateral medulla and COMPASS-31 reduction β₯15 points. Falsified if TSPO-PET SUVR change under 5% or COMPASS-31 change <10 points.
Could NAD+ precursors (NR 300 mg bid or NMN 250 mg qd) combined with apigenin (50 mg qd, a CD38 inhibitor) preserve NAD+ for SIRT1-mediated autonomic and mitochondrial function in GPCR autoantibody-positive ME/CFS? The mechanism: GPCR autoantibody signaling (M3/Gq β IP3 β Ca2+) activates CD38 (the primary NADase), consuming NAD+. Apigenin blocks CD38, preserving NAD+ for SIRT1 which drives PGC-1Ξ±-mediated mitochondrial biogenesis and autonomic regulation. No ME/CFS data on CD38 activity or apigenin effects exist. (Blitshteyn, Doherty, and Steinman 2026)
Falsifiable prediction: Open-label pilot (n=15, 12 weeks) in GPCR AAb+ ME/CFS will show NAD+/NADH ratio increase β₯1.5Γ, SIRT1 activity increase β₯30%, and fatigue reduction β₯8 points (MFI). Falsified if NAD+/NADH ratio increase is below 1.2Γ or fatigue reduction is below 4 points.